Dasakast 70 TABLETS Dasakast-70 contains Dasatinib, an oral multi-kinase inhibitor targeting BCR-ABL kinase and Src family kinases (SRC, LCK, YES, FYN). By binding to active and inactive conformations of the BCR-ABL kinase domain with high potency, it inhibits autophosphorylation and downstream oncogenic signaling pathways, thereby suppressing leukemic cell proliferation and inducing apoptosis. It is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, as well as Ph+ CML and Ph+ acute lymphoblastic leukemia (ALL) resistant or intolerant to prior therapy.